RT Journal Article
SR Electronic
T1 CD177, a specific marker of neutrophil activation, is a hallmark of COVID-19 severity and death
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.12.20246934
DO 10.1101/2020.12.12.20246934
A1 Lévy, Yves
A1 Wiedemann, Aurélie
A1 Hejblum, Boris P.
A1 Durand, Mélany
A1 Lefebvre, Cécile
A1 Surénaud, Mathieu
A1 Lacabaratz, Christine
A1 Perreau, Matthieu
A1 Foucat, Emile
A1 Déchenaud, Marie
A1 Tisserand, Pascaline
A1 Blengio, Fabiola
A1 Hivert, Benjamin
A1 Gautier, Marine
A1 Cervantes-Gonzalez, Minerva
A1 Bachelet, Delphine
A1 Laouénan, Cédric
A1 Bouadma, Lila
A1 Timsit, Jean-François
A1 Yazdanpanah, Yazdan
A1 Pantaleo, Giuseppe
A1 Hocini, Hakim
A1 Thiébaut, Rodolphe
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/12/14/2020.12.12.20246934.abstract
AB COVID-19 SARS-CoV-2 infection exhibits wide inter-individual clinical variability, from silent infection to severe disease and death. The identification of high-risk patients is a continuing challenge in routine care. We aimed to identify factors that influence clinical worsening. We analyzed 52 cell populations, 71 analytes, and RNA-seq gene expression in the blood of severe patients from the French COVID cohort upon hospitalization (n = 61). COVID-19 patients showed severe abnormalities of 27 cell populations relative to healthy donors (HDs). Forty-two cytokines, neutrophil chemo-attractants, and inflammatory components were elevated in COVID-19 patients. Supervised gene expression analyses showed differential expression of genes for neutrophil activation, interferon signaling, T- and B-cell receptors, EIF2 signaling, and ICOS-ICOSL pathways in COVID-19 patients. Unsupervised analysis confirmed the prominent role of neutrophil activation, with a high abundance of CD177, a specific neutrophil activation marker. CD177 was the most highly differentially-expressed gene contributing to the clustering of severe patients and its abundance correlated with CD177 protein serum levels. CD177 levels were higher in COVID-19 patients from both the French and “confirmatory” Swiss cohort (n = 203) than in HDs (P< 0.01) and in ICU than non-ICU patients (P< 0.001), correlating with the time to symptoms onset (P = 0.002). Longitudinal measurements showed sustained levels of serum CD177 to discriminate between patients with the worst prognosis, leading to death, and those who recovered (P = 0.01). These results highlight neutrophil activation as a hallmark of severe disease and CD177 assessment as a reliable prognostic marker for routine care.Competing Interest StatementThe authors have declared no competing interest.Funding StatementANR-10-LABX-77-01 PHRC 20-0424Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We enrolled a subgroup of COVID19 patients of the French COVID cohort (registered at clinicaltrials.gov NCT04262921). Ethics approval was given on February 5th by the French Ethics Committee CPP-Ile-de-France VI (ID RCB: 2020-A00256-33).The Swiss cohort was approved by the ethical commission (CER-VD; Swiss ethics protocol ID: 2020-00620) and all subjects provided written informed consentAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRNA sequencing data that support the findings of this study will be deposited in the Gene Expression Omnibus (GEO) repository. Other data will be provided as Source data files.